Journal of Clinical Pharmacology

• 

  Publication Venue For

  • Population Pharmacokinetic Modeling to Evaluate Standard Magnesium Sulfate Treatments and Alternative Dosing Regimens for Women With Preeclampsia..  59:374-385. 2019
  • Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator..  52:996-1006. 2012
  • Pharmacokinetic-pharmacodynamic modeling of apratastat: a population-based approach..  51:472-481. 2011
  • Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide..  50:554-565. 2010
  • Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination..  48:1309-1322. 2008
  • In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc..  48:1179-1188. 2008
  • The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil..  45:219-226. 2005
  • Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy..  44:1342-1351. 2004
  • Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children..  43:133-140. 2003
  • Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers..  42:1027-1030. 2002
  • Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation..  42:388-394. 2002
  • Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair..  41:972-978. 2001
  • Effect of food and food composition on alcohol elimination rates in healthy men and women.  41:1345-1350. 2001
  • Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics..  37:267-278. 1997
  • Oral ondansetron pharmacokinetics: the effect of chemotherapy..  34:767-773. 1994
  • The mechanism of action of steroid hormones: a new twist to an old tale..  33:1165-1172. 1993
  • A 19-YEAR-OLD MAN WITH ALTERED MENTAL STATUS.  32:511-519. 1992
  • A nineteen-year-old man with altered mental status..  32:511-519. 1992
  • Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients..  32:571-575. 1992
  • Clinical pharmacology training at the Food & Drug Administration..  32:400-406. 1992
  • Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension..  30:425-437. 1990
  • Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension..  29:33-40. 1989
  • Effect of cetamolol on epinephrine-induced hypokalemia..  28:751-756. 1988
  • Falsely elevated urinary excretion of catecholamines and metanephrines in patients receiving labetalol therapy..  27:288-292. 1987
  • EFFECT OF PHENOBARBITAL (PB) ON PHENYTOIN (PHT) BIOTRANSFORMATION DETERMINED BY STABLE ISOTOPE TECHNIQUE.  26:544-544. 1986
  • Combined effect of bumetanide and metolazone in normal volunteers..  25:369-373. 1985
  • Treatment of chronic orthopedic pain with zomepirac..  20:385-391. 1980
  • TREATMENT OF CHRONIC ORTHOPEDIC PAIN WITH ZOMEPIRAC.  20:385-391. 1980
  • Treatment of chronic orthopedic pain with zomepirac.  20:385-391. 1980
  • SIROLIMUS DOSE-NORMALIZED TROUGHS WERE AFFECTED BY TIME POST SIROLIMUS INITIATION, CONCOMITANT TACROLIMUS THERAPY, AND MDR-1 3435C > T POLYMORPHISM IN RENAL TRANSPLANT PATIENTS WHO ARE CYP3A5 NON-EXPRESSERS 2009